What did Bernstein do for the LLY analyst rating on March 10, 2026?

Bernstein reiterated an **Outperform** rating for Eli Lilly on March 10, 2026 and did not publish a new price target in the note. The stance was maintained rather than upgraded or downgraded.

How should investors interpret the maintained Outperform for LLY?

A maintained Outperform signals continued analyst confidence. Investors should see it as positive endorsement, balance it with valuation, and consider pipeline and regulatory risks before acting.

Did the Bernstein note move LLY stock price materially?

No. The market reaction was muted. The noted price change since the comment is **-0.73% (-$7.32)**, showing limited immediate impact from the maintained rating.

How does Meyka AI view the LLY analyst rating overall?

Meyka AI tracks analyst coverage and assigns **LLY a grade of A** based on multiple factors. This grade reflects consensus and fundamentals but is not investment advice.

Analyst Ratings

Bernstein Maintains Outperform on Eli Lilly (LLY) March 2026

ByHuzaifa Zahoor March 11, 2026

Bernstein maintained an Outperform rating on Eli Lilly and Company (LLY) on March 10, 2026. This note did not include a fresh price target and left the analyst stance unchanged. Our LLY analyst rating review summarizes the note, market reaction, and investor implications. Bernstein’s reiteration follows continued positive sales momentum for key drugs. Meyka AI rates LLY with a grade of A based on benchmark, sector, growth, metrics, and analyst consensus.